Page 6,167«..1020..6,1666,1676,1686,169..6,1806,190..»

Total hip replacement surgery increases risk of stroke, study suggests

Posted: Published on November 10th, 2012

ScienceDaily (Nov. 9, 2012) An international study involving the University of Southampton has shown people who undergo a total hip replacement are at a higher risk of a stroke in the first two weeks after surgery. The cohort study, published in the American Heart Association journal Stroke, assessed about 66,000 people in the Netherlands who had total hip replacements and compared them to people who shared their age and sex, but who did not have the procedure. Results showed that patients were five times as likely to have an ischaemic stroke within the first two weeks after a total hip replacement and were four times as likely to have a haemorrhagic stroke after the same procedure. After the first two weeks, the risk dropped steadily but remained elevated during at least the first six weeks for ischaemic stroke and the first 12 weeks for haemorrhagic stroke. A haemorrhagic stroke is caused by bleeding in the brain and an ischemic stroke is caused by artery blockage. However another aspect of the study, which was the largest one of its kind, demonstrated that patients who took antiplatelet drugs, such as aspirin, prior to surgery lowered their risk of ischaemic stroke in the … Continue reading →

Comments Off on Total hip replacement surgery increases risk of stroke, study suggests

Kessler Foundation stroke expert receives $145,000 grant from Healthcare Foundation of New Jersey

Posted: Published on November 10th, 2012

Public release date: 9-Nov-2012 [ | E-mail | Share ] Contact: Carolann Murphy CMurphy@KesslerFoundation.org 973-324-28382 Kessler Foundation West Orange, NJ. November 9, 2012. A.M. Barrett, MD, director of stroke rehabilitation research at Kessler Foundation, was awarded a $145,000 grant (#2733) by The Healthcare Foundation of New Jersey. The grant will enable the Stroke Research team and Dr. Barrett, an expert in hidden disabilities after stroke, to extend their work in hidden disabilities to stroke survivors and their health care providers in Newark, New Jersey. Dr. Barrett and her team are well known for their research on the hidden disability of functional vision known as spatial neglect. Their investigations focus on the use of optical prism therapy for this disabling complication of stroke. Hidden disabilities that impair functional vision affect as many as one out of three stroke survivors. They are the underlying cause of accidents, falls, injuries that prolong recovery and increase costs for rehabilitation. To address these common disabling complications of stroke, greater awareness is needed, as well as education for healthcare providers, according to Dr. Barrett. This will lead to better care for people recovering from the cognitive effects of stroke. "Preliminary testing of Kessler Foundation's optical prism … Continue reading →

Comments Off on Kessler Foundation stroke expert receives $145,000 grant from Healthcare Foundation of New Jersey

Research and Markets: Global Acute Ischemic Stroke Epidemiology and Patient Flow Analysis – 2012

Posted: Published on November 10th, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/j2dxhz/global_acute) has announced the addition of the "Global Acute Ischemic Stroke Epidemiology and Patient Flow Analysis - 2012" report to their offering. Fore Pharma announced the results of its Acute Ischemic Stroke patient population study in a new report Global Acute Ischemic Stroke Epidemiology and Patient Flow Analysis - 2012'. The report provides insights into Acute Ischemic Stroke epidemiology, Acute Ischemic Stroke diagnosed patients, and Acute Ischemic Stroke treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Acute Ischemic Stroke derived from epidemiological analysis, percentage of patients diagnosed with Acute Ischemic Stroke, and percentage of patients treated with Acute Ischemic Stroke therapy. This study helps executives estimate Acute Ischemic Stroke market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions. This report provides estimates and forecasts of Acute Ischemic Stroke prevalence, Acute Ischemic Stroke diagnosis rate, and Acute Ischemic Stroke treatment rate for the period 2012-2019. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and … Continue reading →

Comments Off on Research and Markets: Global Acute Ischemic Stroke Epidemiology and Patient Flow Analysis – 2012

Neuralstem Reports Third Quarter Financial Results And Provides Update On Clinical Programs And Business Highlights

Posted: Published on November 10th, 2012

ROCKVILLE, Md., Nov.9, 2012 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) reported its financial results for the three months and nine months ended September 30, 2012 and provided an update on clinical programs and business highlights. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) "In the third quarter, the company achieved three significant clinical milestones. The first was the completion of the eighteenth and final surgery in our ALS Phase I trial. All ALS trial assessments show the NSI-566 neural stem cells and intraspinal transplantation procedure, the first in the world, to be safe. The trial's principal investigator, Dr. Eva Feldman, said she believes we are seeing evidence of a treatment effect in some Phase I patients over a sustained period of time. We look forward to advancing to the next ALS trials, to increase both number of patients treated and NSI-566 dosage, and effectively evaluate efficacy. To that end, we are working diligently with our investigators to file an IND with the FDA for a Phase II ALS trial by year-end," said Karl Johe, PhD, Chairman of Neuralstem's Board of Directors and Chief Scientific Officer. "The second significant clinical milestone was approval to begin our ischemic stroke trial in China. Our collaborators in Beijing, at … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Neuralstem Reports Third Quarter Financial Results And Provides Update On Clinical Programs And Business Highlights

Talk explores value of dance therapy for Parkinson’s patients

Posted: Published on November 10th, 2012

Forty people bobbed their heads and swung their feet to Dont Worry, Be Happy as the second installment of the Creative Medicine Series kicked off last night. The lecture and interactive workshop, Artists and Scientists as Partners: Dance, Music and Neuroscience, focused on the power of dance as a therapeutic tool for individuals diagnosed with Parkinsons Disease and Autism Spectrum Disorders. The Creative Medicine Series is the result of a collaboration between the Cogut Center for the Humanities, the Creative Arts Council and the Department of Emergency Medicine at Alpert Medical School. Are we ready to move our hips? lecturer Rachel Balaban asked the diverse crowd of students, dancers, Parkinsons patients and doctors as the audience loosened up. Balaban is the regional coordinator for Dance for Parkinsons Disease, a program that teaches dance to individuals with Parkinsons. Dance classes help Parkinsons patients to regain some of the fluidity and ease of movement they once took for granted, Balaban said, citing improved stability, reduction in tremor and a greater sense of social inclusion as some of the programs main benefits to participants with neurodegenerative disorders. Balaban was joined by Julie Adams Strandberg, professor of theater arts and performance studies, who spoke … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Talk explores value of dance therapy for Parkinson’s patients

RBCC and Amarantus BioSciences Outline Terms for NuroPro Parkinson's Blood Test Joint Venture

Posted: Published on November 10th, 2012

NOKOMIS, Fla., & SUNNYVALE, Calif.--(BUSINESS WIRE)-- Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (RBCC), and Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinsons disease and Traumatic Brain Injury, have finalized the framework of their proposed joint venture (JV) and will execute material definitive agreements within 30 days. The JVs first priority will be to advance Amarantus NuroPro Parkinsons Diagnostic Blood Test (NuroPro) towards commercialization. NuroPro works by identifying differentiated levels proteins and peptides in the blood of patients who have Parkinsons disease, versus those who do not. Under the terms of the pending agreement, RBCC will invest $150,000 in various funding tranches to re-establish the NuroPro 2D Gel platform and re-analyze samples from the previous Phase 1 clinical trial. Thereafter, the JV will further fund the Phase 2 clinical trial. RBCC will be repaid for their investment out of proceeds from the sales generated by NuroPro and will share revenues once the initial investment is repaid. RBCC has received a commitment from private, outside sources to provide the capital necessary to fund the JV. NuroPro has completed a Phase 1 human clinical trial, and JV will initiate a Phase 2 clinical … Continue reading →

Posted in Parkinson's Treatment | Comments Off on RBCC and Amarantus BioSciences Outline Terms for NuroPro Parkinson's Blood Test Joint Venture

Amarantus Biosciences and RBCC Outline Terms for NuroPro Parkinson's Blood Test Joint Venture

Posted: Published on November 10th, 2012

NOKOMIS, Fla., and SUNNYVALE, Calif., Nov. 9, 2012 /PRNewswire/ --Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (RBCC), and Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury, have finalized the framework of their proposed joint venture (JV) and expect to execute material definitive agreements within 30 days, subject to closing documents. The JV's first priority will be to advance Amarantus' NuroPro Parkinson's Diagnostic Blood Test ("NuroPro") towards commercialization. NuroPro works by identifying differentiated levels of proteins and peptides in the blood of patients who have Parkinson's disease, versus those who do not. Under the terms of the pending agreement, RBCC will invest $150,000 over a 6 month period in various funding tranches to re-establish the NuroPro 2D Gel platform and re-analyze samples from the previous Phase 1 clinical trial. Thereafter, the JV will further fund the Phase 2 clinical trial. RBCC will be repaid for their investment out of proceeds from the sales generated by NuroPro and will share revenues once the initial investment is repaid. RBCC has received a commitment from private, outside sources to provide the capital necessary to fund the JV. NuroPro has completed … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Amarantus Biosciences and RBCC Outline Terms for NuroPro Parkinson's Blood Test Joint Venture

Family launches £40,000 campaign to help Cockermouth girl Megan

Posted: Published on November 10th, 2012

Last updated at 16:14, Friday, 09 November 2012 A Cockermouth mother has launched a campaign to raise 40,000 for pioneering treatment that could help her disabled daughter. FUND-TASTIC: Friends and family of Cockermouth School pupil Megan White, who was born with cerebral palsy, are raising funds to help pay for pioneering treatment. From left: mum Kerrie Iredale, Megan, 12, twin sister Leah, little sister Kara Beattie, five, and grandmother Peggy Bradshaw If the treatment works, Kerrie Iredale, of Bellbrigg Lonning, hopes daughter Megan White will one day fulfil her dream of being able to ride a bike. Megan was born 10 weeks premature and has cerebral palsy and spastic diplegia. The Cockermouth School pupils condition means she has trouble walking and has poor co-ordination. She uses a walking frame, stick or wheelchair to get around but would love a bicycle. In 2008 she had an operation to straighten her right foot but the results were not what the family had expected. Kerrie, 35, said Megans confidence took a turn for the worse and she took months to recover. Now Kerrie wants to raise money so that Megan, who has a twin sister Leah, can have stem cell treatment only available … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on Family launches £40,000 campaign to help Cockermouth girl Megan

Hunting neuron killers in Alzheimer's and traumatic brain injury

Posted: Published on November 10th, 2012

ScienceDaily (Nov. 9, 2012) Sanford-Burnham researchers discovered that the protein appoptosin prompts neurons to commit suicide in several neurological conditions -- giving them a new therapeutic target for Alzheimer's disease and traumatic brain injury. Dying neurons lead to cognitive impairment and memory loss in patients with neurodegenerative disorders-conditions like Alzheimer's disease and traumatic brain injury. To better diagnose and treat these neurological conditions, scientists first need to better understand the underlying causes of neuronal death. Enter Huaxi Xu, Ph.D., professor in Sanford-Burnham's Del E. Webb Neuroscience, Aging, and Stem Cell Research Center. He and his team have been studying the protein appoptosin and its role in neurodegenerative disorders for the past several years. Appoptosin levels in the brain skyrocket in conditions like Alzheimer's and stroke, and especially following traumatic brain injury. Appoptosin is known for its role in helping the body make heme, the molecule that carries iron in our blood (think "hemoglobin," which makes blood red). But what does heme have to do with dying brain cells? As Xu and his group explain in a paper they published recently in the Journal of Neuroscience, excess heme leads to the overproduction of reactive oxygen species, which include cell-damaging free radicals … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Hunting neuron killers in Alzheimer's and traumatic brain injury

I lose weight fast at the Weight Loss Center of Tulsa – Video

Posted: Published on November 10th, 2012

I lose weight fast at the Weight Loss Center of Tulsa Lose weight fast at the Weight Loss Center of Tulsa by visiting http://www.weightlosscenteroftulsa.com today. Dr. Rebecca Ward has developed several of the most effective weight loss programs in America and continues to be Tulsa's premier weight loss expert. Lose with with one of our weight loss program s including HCG, Hormone Replacement, Adrenal Fatigue Correction, Stress-Reduction weight loss, and Detoxification weight loss. Lose weight Tulsa with Dr. Rebecca Ward and the amazing weight loss program s at the Weight Loss Center of Tulsa.From:WeightLossofTulsaViews:0 0ratingsTime:01:01More inHowto Style View post: I lose weight fast at the Weight Loss Center of Tulsa - Video … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on I lose weight fast at the Weight Loss Center of Tulsa – Video

Page 6,167«..1020..6,1666,1676,1686,169..6,1806,190..»